Literature DB >> 20682972

RB stabilizes XPC and promotes cellular NER.

Tabitha M Hardy1, Ma Suresh Kumar, Martin L Smith.   

Abstract

It has long been thought that the G(1)/S cell cycle checkpoint allows time for DNA repair by delaying S-phase entry. The p53 tumor suppressor pathway regulates the G(1)/S checkpoint by regulating the cyclin-dependent kinase inhibitor p21(Waf1/Cip1), but p53 also regulates the nucleotide excision DNA repair protein XPC. Here, using p53-null cell lines we show that additional mechanisms stabilize XPC protein and promote nucleotide excision repair (NER) in concert with the G(1)/S checkpoint. At least one mechanism to stabilize and destabilize XPC involves ubiquitin-mediated degradation of XPC, as the ubiquitin ligase inhibitor MG-132 blocked XPC degradation. The retinoblastoma protein RB, in its unphosphorylated form actually stabilized XPC and promoted NER as measured by host cell reactivation experiments. The data suggest that XPC protein and XPC-mediated NER are tightly linked to the G(1)/S checkpoint, even in cells lacking functional p53.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20682972

Source DB:  PubMed          Journal:  Anticancer Res        ISSN: 0250-7005            Impact factor:   2.480


  4 in total

1.  Defective DNA repair and cell cycle arrest in cells expressing Merkel cell polyomavirus T antigen.

Authors:  Stephanie K Demetriou; Katherine Ona-Vu; Erin M Sullivan; Tiffany K Dong; Shu-Wei Hsu; Dennis H Oh
Journal:  Int J Cancer       Date:  2012-05-29       Impact factor: 7.396

Review 2.  XPC: Going where no DNA damage sensor has gone before.

Authors:  Leah Nemzow; Abigail Lubin; Ling Zhang; Feng Gong
Journal:  DNA Repair (Amst)       Date:  2015-09-09

Review 3.  Molecular regulation of UV-induced DNA repair.

Authors:  Palak Shah; Yu-Ying He
Journal:  Photochem Photobiol       Date:  2015-01-14       Impact factor: 3.421

Review 4.  The Retinoblastoma (RB) Tumor Suppressor: Pushing Back against Genome Instability on Multiple Fronts.

Authors:  Renier Vélez-Cruz; David G Johnson
Journal:  Int J Mol Sci       Date:  2017-08-16       Impact factor: 5.923

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.